Oruka Therapeutics, Inc.
ORKA- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0000907654
In the last 90 days, Oruka Therapeutics, Inc. insiders filed 0 open-market purchases and 16 sales; 255 institutions reported holding it in 13F filings for Q2 2026, worth $7.05B in total; Viking Global Investors is the only superinvestor holding it.
Key figures
- Insider buysOpen market, last 90 days
- 0
- Insider sellsLast 90 days, $319.8M in total
- 16
- 13F holdersQ2 2026, +73 vs. previous quarter
- 255
- 13F valueReported value at the end of Q2 2026
- $7.05B
- Superinvestors holdingAt the end of Q2 2026
- 1
Price chart
Superinvestors holding ORKA, Q2 2026
1 superinvestor reports holding Oruka Therapeutics, Inc. on Form 13F. Percentages are the stock's share of each portfolio.
Viking Global Investors
Andreas Halvorsen
0.4%
Oruka Therapeutics, Inc.'s share of the portfolio
- Shares
- 1,503,478
- Value
- $143.1M
Latest insider trades
Open-market purchases and sales by Oruka Therapeutics, Inc. insiders from Form 4, newest first.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Sep 21, 2026 (view filing)5:38 PM ET | Sep 21 | Same day | Agarwal ArjunSenior Vice President, Finance | SSale | −533 | $95.75 | −$51.0K | −3.6%14.2K after | 10b5-1 |
| Sep 21, 2026 (view filing)4:57 PM ET | Sep 21 | Same day | Quinlan Paul TGeneral Counsel | SSale | −10.0K | $93.64 | −$936.4K | −25.0%30.0K after | 4 lots10b5-1 |
| Sep 15, 2026 (view filing)7:18 PM ET | Sep 15 | Same day | Goncalves JoanaChief Medical Officer | SSale | −7.95K | $92.38 | −$734.1K | −20.0%31.8K after | 5 lots10b5-1 |
| Sep 15, 2026 (view filing)7:17 PM ET | Sep 11-15 | 4 days | Agarwal ArjunSenior Vice President, Finance | SSale | −10.0K | $92.43 | −$926.0K | −40.4%14.8K after | 5 lots10b5-1 |
| Sep 15, 2026 (view filing)7:15 PM ET | Sep 15 | Same day | Klein Lawrence OttoChief Executive Officer | SSale | −2.45K | $95.71 | −$234.7K | −0.3%923.1K after | |
| Sep 15, 2026 (view filing)7:14 PM ET | Sep 15 | Same day | Quinlan Paul TGeneral Counsel | SSale | −1.04K | $95.71 | −$99.4K | −3.3%30.0K after | |
| Sep 15, 2026 (view filing)7:11 PM ET | Sep 15 | Same day | Sandler Laura LeeChief Operating Officer | SSale | −906 | $95.71 | −$86.7K | −0.4%235.5K after | |
| Sep 1, 2026 (view filing)6:36 PM ET | Sep 1 | Same day | Sandler Laura LeeChief Operating Officer | SSale | −5.00K | $91.82 | −$459.1K | −2.1%236.4K after | 2 lots10b5-1 |
| Sep 1, 2026 (view filing)6:35 PM ET | Sep 1 | Same day | Klein Lawrence OttoChief Executive Officer | SSale | −75.0K | $91.83 | −$6.89M | −7.5%925.6K after | 3 lots10b5-1 |
| Aug 17, 2026 (view filing)6:09 PM ET | Aug 17 | Same day | Goncalves JoanaChief Medical Officer | SSale | −7.00K | $111.84 | −$782.9K | −17.6%32.7K after | 4 lots10b5-1 |
Top 10 13F holders, Q2 2026
The largest institutional positions in Oruka Therapeutics, Inc. at the end of Q2 2026; share changes are against Q1 2026.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| FMR LLC | 9,057,645 | $862.0M | 0.04% | +1,626,242+21.9% | Added |
| BlackRock, Inc. | 4,990,181 | $474.9M | 0.01% | +1,463,094+41.5% | Added |
| VR Adviser, LLC | 4,148,428 | $394.8M | 11.97% | 00.0% | Unchanged |
| Fairmount Funds Management LLC | 3,705,262 | $352.6M | 23.31% | 00.0% | Unchanged |
| Capital World Investors | 3,401,639 | $323.7M | 0.04% | +3,401,639 | New |
| RTW Investments, LP | 3,139,030 | $298.7M | 2.55% | +1,080,882+52.5% | Added |
| State Street Corp | 2,673,090 | $254.4M | 0.01% | +1,059,629+65.7% | Added |
| Vanguard Capital Management LLC | 2,360,971 | $224.7M | 0.00% | +501,340+27.0% | Added |
| Paradigm Biocapital Advisors LP | 2,144,526 | $204.1M | 3.82% | −175,790−7.6% | Reduced |
| Deep Track Capital, LP | 1,926,000 | $183.3M | 2.70% | −108,203−5.3% | Reduced |